| Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. | |
| | |
MedLine Citation:
|
PMID: 17725415 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The presence of drug-associated mutations among ART-naive, HIV-1(+) patients may compromise the response to antiviral therapy. We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV). Study FTC-301A compared emtricitabine once daily (QD) with stavudine twice daily in combination with didanosine and efavirenz in ART-naive patients. Genotypic analysis was performed on baseline plasma HIV-1 RNA for all available samples and at time of virologic failure (VF). Drug resistance mutations present at baseline were evaluated as predictors of VF using logistic regression. VF rates were compared between subgroups using a two-sided exact test. Baseline drug resistance mutations were observed in 90/546 (16.5%) patients: 56/90 (62.2%) with nonnucleoside analogue (NNRTI) mutations and 42/90 (46.6%) with nucleoside analogue mutations. In a stepwise, multiple regression analysis, the presence of the K103N mutation at initiation of therapy was associated with VF in both arms (p = 0.001), however, there was a higher incidence of VF in the stavudine arm compared to the emtricitabine arm regardless of the presence or absence of mutations at baseline (p = 0.001). In this study, the presence of drug-associated resistance mutations in ART-naive patients was significantly correlated with subsequent development of virologic failure underscoring the utility of testing for resistance in addition to the use of potent and well-tolerated first line regimens in treatment-naive patients. |
| | |
Authors:
|
Katyna Borroto-Esoda; Joshua M Waters; Andrew S Bae; Jeanette L Harris; John E Hinkle; Joseph B Quinn; Frank S Rousseau |
Related Documents
:
|
16797735 - L-nucleoside enantiomers as antivirals drugs: a mini-review. 23075415 - Overlooked and underestimated? problematic alcohol use in clients recovering from drug ... 15989655 - Viral resistance patterns selected by antiretroviral drugs and their potential to guide... 9623975 - Predicting and preventing the emergence of antiviral drug resistance in hsv-2. 3145445 - Behavioral studies of the reinforcing properties of cocaine. 23673185 - Do general practitioners know what they are prescribing? |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: AIDS research and human retroviruses Volume: 23 ISSN: 0889-2229 ISO Abbreviation: AIDS Res. Hum. Retroviruses Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-29 Completed Date: 2007-12-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8709376 Medline TA: AIDS Res Hum Retroviruses Country: United States |
Other Details:
|
Languages: eng Pagination: 988-95 Citation Subset: IM; X |
Affiliation:
|
Gilead Sciences, Inc., 4611 University Drive, Durham, North Carolina 27707, USA. kborrotoesoda@gilead.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anti-HIV Agents / therapeutic use* Antiretroviral Therapy, Highly Active* Benzoxazines / therapeutic use Deoxycytidine / analogs & derivatives, therapeutic use Didanosine / therapeutic use Drug Resistance, Viral / genetics* Female Genotype HIV Infections / drug therapy*, virology HIV-1* Humans Male Middle Aged Regression Analysis Stavudine / therapeutic use Treatment Failure |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/Benzoxazines; 0/emtricitabine; 154635-17-3/efavirenz; 3056-17-5/Stavudine; 69655-05-6/Didanosine; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: No observable correlation between central nervous system side effects and EFV plasma concentrations ...
Next Document: Effects of HIV type 1 infection on hematopoiesis in Botswana.